Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: Clinical data

Gut

Volumn 49, Issue SUPPL. 4, 2001, Pages

  Hesse, U ^a   Ysebaert, D ^a   De Hemptinne, B ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; GLUCAGON; OCTREOTIDE; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ABDOMINAL DRAINAGE; ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; GASTROINTESTINAL SECRETION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCAR FORMATION; TACHYCARDIA;

EID: 5744254624     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.suppl_4.iv11     Document Type: Article

References (42)

1. Classification and pathophysiology of enterocutaneous fistulas
2. Review of 404 patients with gastrointestinal fistulas. Impact of parenteral nutrition
3. One hundred and fourteen fistulas of the gastrointestinal tract treated with total parenteral nutrition
4. Management of patients with a short bowel
5. Somatostatin and octreotide: Physiological background and pharmacological application
6. Developing guidelines
7. Is octreotide a new hope for enterocutaneous and external pancreatic fistulas closure?
8. Reoperative versus conservative management for gastrointestinal fistulas
9. Fistulas of the upper gastrointestinal tract
10. Parenteral and enteral nutrition and the enterocutaneous fistula treatment. II. Factors influencing the outcome of treatment
11. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin
12. Treatment of external gastrointestinal fistulas by a combination of total parenteral nutrition and somatostatin
13. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man
14. Pharmacokinetics of SMS 201-995 in healthy subjects
15. Fluctuations in the secretion of pancreatic enzymes between consecutive doses of octreotide: Implications for the management of fistulae
16. Octreotide for treatment of postoperative alimentary tract fistulas
17. Inhibition of pancreatic secretion under long-term octreotide treatment in humans
18. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration
19. Octreotide
20. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumours: Consequences with regard to diagnosis, localization, and therapy
21. Somatostatin binding in human gastrointestinal tissues: Effects of cations and somatostatin analogues
22. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial
23. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula
24. Somatostatin for enterocutaneous fistula: A silver bullet?
25. Somatostatin in the management of gastrointestinal fistulas
26. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output
27. Octreotide and postoperative enterocutaneous fistulae: A controlled prospective study
28. Somatostatin and/or total parenteral nutrition for the treatment of intestinal fistulas
29. Management of digestive fistulas
30. Treatment of enterocutaneous fistulas with somatostatin
31. Somatostatin analog treatment of pancreatic fistulas
32. Treatment of external pancreatic fistulas with somatostatin. Second place winner: Conrad Jobst award
33. Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995
34. Short report: Octreotide in the treatment of external pancreatic fistulas
35. Somatostatin in the management of gastrointestinal fistulas. Invited commentary
36. Adjuvant therapy with somatostatin i.v. in post-operative fistulae of the pancreas, gall bladder and small intestine. A multicentre, randomised study
37. Treatment of enterocutaneous fistulae with or without octreotide and parenteral nutrition
38. Treatment of enterocutaneous fistulas with TPN and somatostatin, compared with patients who received TPN only
39. Treatment of pancreatic fistulas with somatostatin and total parenteral nutrition
40. A drug adjunct for postoperative external alimentary tract fistulas
41. Treatment of pancreatic ascites and external pancreatic fistulas with a long-acting somatostatin analogue (Sandostatin)